Agilent, GKPC-330, AdvanceBio InstantPC G1FS1 α(2,3) / FA2G1S(3)1 N-glycan standard

AdvanceBio InstantPC G1FS1 α(2,3) / FA2G1S(3)1 N-glycan standard . N-glycan (mono-α(2,3)-sialylated, mono-galactosylated, biantennary with core fucose) labeled with InstantPC, for use as a qualitative standard in applications such as liquid chromatography (LC). Alternative glycan names: G1FS1, FA2G(4)1S(3)1.

Specifications:
Chemical Structure:
Label: InstantPC
Monoisotopic Mass: MWGlycan + 261.14773 = 2176.8404
Name: G1FS1 (α2,3)
Oxford Name: FA2G(4)1S(3)1
Standard Type: Complex-type Native N-Glycan
Unit: 25 Injections

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
This N glycan standard provides laboratories with a reliable reference for the qualitative and quantitative analysis of glycosylation patterns in biopharmaceuticals and glycoproteins. Labeled with the sensitive InstantPC fluorophore, its composition encompasses G1FS1 α(2,3) and FA2G1S(3)1 isomeric structures, supporting comprehensive glycan profiling and method development. The standard is ideal for use in applications such as structural elucidation, assay calibration, and system suitability testing in analytical workflows.

This product is specifically formulated for use with Agilent AdvanceBio Glycan Mapping workflows and is fully compatible with high performance liquid chromatography (HPLC) and ultra high performance liquid chromatography (UHPLC) systems equipped with fluorescence and mass spectrometric detectors. Researchers in biopharmaceutical development, quality control, and glycomics can use this standard to enhance accuracy and reproducibility in their analyses. It is also recommended for use alongside AdvanceBio Glycan Mapping columns and InstantPC labeling kits for optimal performance. Its well defined glycan content ensures traceability and confidence in data interpretation, making it an essential tool for anyone performing detailed N glycan analysis in the context of therapeutic protein characterization and regulatory compliance.